India, July 28 -- Kiniksa Pharmaceuticals International plc (KNSA) reported second-quarter 2026 results, highlighting robust revenue growth from ARCALYST, its IL-1 inhibitor for recurrent pericarditis, and continued progress across its cardiovascular pipeline.
For Q2 2026, ARCALYST net product revenue reached $243.6 million, representing approximately 55% year-over-year growth compared with $156.8 million in Q2 2025. Net income for Q2 2026 was $25.4 million, or $0.30 per diluted share, compared with $17.8 million, or $0.23 per diluted share in Q2 2025, reflecting strong commercial execution and operating leverage.
Approximately 21% of the 14,000 multiple-recurrence pericarditis patients were actively on therapy by quarter-end, with more t...